Samar Hameed
Internal Medicine · Livingston, NJNPI 1861640518
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,742 of the $2,387 with a category attached, or 73.0%. 16 manufacturers reported payments, led by Modernatx, Inc. at 41.9% of the total. 2024 is the largest year on record at $1,000, 2.5 times the $407 reported in 2019.
Across 100 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$1000
- Novo Nordisk$553
- Sanofi-aventis U.S. LLC$165
- Lilly USA, LLC$140
- Pfizer$117
- Boehringer Ingelheim$93
- plus $318 from 10 others
Across 411 payments — averaging $8822.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$1.7M
- Eli Lilly$980K
- Boehringer Ingelheim$429K
- Pfizer$310K
- Boehringer Ingelheim International GmbH$137K
- Amgen$91K
- plus $6K from 1 others
What the payments were for
- Travel & lodging$64527%
- Food & beverage$1,74273%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 8 | $1,000 |
| Novo Nordisk | 37 | $553 |
| Sanofi-aventis U.S. LLC | 11 | $165 |
| Lilly USA, LLC | 10 | $140 |
| Pfizer | 8 | $117 |
| Boehringer Ingelheim | 7 | $93 |
| Dynavax Technologies Corporation | 5 | $91 |
| Daiichi Sankyo Inc. | 3 | $38 |
| Merck | 2 | $34 |
| AstraZeneca | 2 | $33 |
| Amgen | 2 | $29 |
| Exact Sciences | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $24 |
| AbbVie | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
How this compares
$2,387 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 29 | $314 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Livingston
- Martin BedigianLivingston$240K
- Noah RosenbergLivingston$144K
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Rameck HuntPlainsboro$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.